PF-514273

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PF-514273
PF-514,273 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C21H17Cl2F2N3O2
Molar mass 452.281 g/mol
3D model (JSmol)
 NYesY (what is this?)

PF-514273 is a drug developed by Pfizer, which acts as an extremely selective antagonist for the CB1 receptor, with approximately 10,000x selectivity over the closely related CB2 receptor. This very high selectivity makes it useful for scientific research into these receptors, as many commonly used cannabinoid receptor antagonists also block the CB2 receptor to some extent.[1]

References[edit]

  1. ^ Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, Schneider SR, Paight ES, Griffith DA, Scott DO, O'Connor RE, Nduaka CI. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. Journal of Medicinal Chemistry. 2009 May 14;52(9):2652-5. PMID 19351113